Pasithea Therapeutics (KTTA) Restructuring Costs (2022 - 2025)
Pasithea Therapeutics recorded quarterly Restructuring Costs of $45.0 in Q2 2025, down 93.13% quarter-over-quarter from $655.0 in Q1 2025.
Pasithea Therapeutics' Restructuring Costs history runs 2 years deep, the most recent figure standing at $45.0 for Q2 2025.
- In Q2 2025, Restructuring Costs changed N/A year-over-year to $45.0; the TTM figure through Dec 2025 stood at $700.0 (changed N/A YoY), while the FY2025 annual figure was $700.0, changed N/A from the prior year.
- Restructuring Costs came in at $45.0 for Q2 2025 at Pasithea Therapeutics, down from $655.0 in the prior quarter.
- In the past five years, Restructuring Costs ranged from a high of $326380.0 in Q1 2022 to a low of $45.0 in Q2 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn |
| 10 | Pasithea Therapeutics | 17.41 Mn | 17.41 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2025 | 45.00 |
| Mar 31, 2025 | 655.00 |
| Mar 31, 2022 | 326,380.00 |